nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—Cytarabine—lymphatic system cancer	0.0833	0.318	CbGbCtD
Dantrolene—CYP3A4—Teniposide—lymphatic system cancer	0.0821	0.313	CbGbCtD
Dantrolene—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0574	0.219	CbGbCtD
Dantrolene—CYP3A4—Vincristine—lymphatic system cancer	0.0395	0.151	CbGbCtD
Dantrolene—Muscular weakness—Vincristine—lymphatic system cancer	0.00269	0.00364	CcSEcCtD
Dantrolene—Haematuria—Bleomycin—lymphatic system cancer	0.00269	0.00364	CcSEcCtD
Dantrolene—Pruritus—Mechlorethamine—lymphatic system cancer	0.00268	0.00363	CcSEcCtD
Dantrolene—Pleural effusion—Methotrexate—lymphatic system cancer	0.00266	0.00361	CcSEcCtD
Dantrolene—Anorexia—Teniposide—lymphatic system cancer	0.00266	0.00361	CcSEcCtD
Dantrolene—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.00264	0.00358	CcSEcCtD
Dantrolene—Convulsion—Fludarabine—lymphatic system cancer	0.0026	0.00353	CcSEcCtD
Dantrolene—Necrosis—Methotrexate—lymphatic system cancer	0.0026	0.00352	CcSEcCtD
Dantrolene—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00259	0.00351	CcSEcCtD
Dantrolene—Myalgia—Fludarabine—lymphatic system cancer	0.00256	0.00347	CcSEcCtD
Dantrolene—Haemoglobin—Bleomycin—lymphatic system cancer	0.00254	0.00345	CcSEcCtD
Dantrolene—Haemorrhage—Bleomycin—lymphatic system cancer	0.00253	0.00343	CcSEcCtD
Dantrolene—Discomfort—Fludarabine—lymphatic system cancer	0.00253	0.00343	CcSEcCtD
Dantrolene—Confusional state—Fludarabine—lymphatic system cancer	0.00247	0.00335	CcSEcCtD
Dantrolene—Depression—Carmustine—lymphatic system cancer	0.00245	0.00333	CcSEcCtD
Dantrolene—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00245	0.00332	CcSEcCtD
Dantrolene—Decreased appetite—Teniposide—lymphatic system cancer	0.00243	0.00329	CcSEcCtD
Dantrolene—Renal failure—Carmustine—lymphatic system cancer	0.00242	0.00328	CcSEcCtD
Dantrolene—Vomiting—Mechlorethamine—lymphatic system cancer	0.00241	0.00326	CcSEcCtD
Dantrolene—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0024	0.00326	CcSEcCtD
Dantrolene—Rash—Mechlorethamine—lymphatic system cancer	0.00239	0.00324	CcSEcCtD
Dantrolene—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00238	0.00323	CcSEcCtD
Dantrolene—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00237	0.00321	CcSEcCtD
Dantrolene—Speech disorder—Methotrexate—lymphatic system cancer	0.00237	0.00321	CcSEcCtD
Dantrolene—Flushing—Bleomycin—lymphatic system cancer	0.00235	0.00318	CcSEcCtD
Dantrolene—Depression—Vincristine—lymphatic system cancer	0.00234	0.00318	CcSEcCtD
Dantrolene—Anorexia—Fludarabine—lymphatic system cancer	0.00234	0.00317	CcSEcCtD
Dantrolene—Extravasation—Methotrexate—lymphatic system cancer	0.00234	0.00317	CcSEcCtD
Dantrolene—Feeling abnormal—Teniposide—lymphatic system cancer	0.0023	0.00312	CcSEcCtD
Dantrolene—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00229	0.0031	CcSEcCtD
Dantrolene—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00228	0.00309	CcSEcCtD
Dantrolene—Chills—Bleomycin—lymphatic system cancer	0.00227	0.00308	CcSEcCtD
Dantrolene—Sweating—Vincristine—lymphatic system cancer	0.00225	0.00305	CcSEcCtD
Dantrolene—Renal failure—Mitoxantrone—lymphatic system cancer	0.00225	0.00305	CcSEcCtD
Dantrolene—Nausea—Mechlorethamine—lymphatic system cancer	0.00225	0.00305	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00223	0.00303	CcSEcCtD
Dantrolene—Haemoglobin—Carmustine—lymphatic system cancer	0.00222	0.00301	CcSEcCtD
Dantrolene—Urticaria—Teniposide—lymphatic system cancer	0.00222	0.00301	CcSEcCtD
Dantrolene—Haemorrhage—Carmustine—lymphatic system cancer	0.00221	0.00299	CcSEcCtD
Dantrolene—Body temperature increased—Teniposide—lymphatic system cancer	0.00221	0.00299	CcSEcCtD
Dantrolene—Abdominal pain—Teniposide—lymphatic system cancer	0.00221	0.00299	CcSEcCtD
Dantrolene—Erythema—Bleomycin—lymphatic system cancer	0.0022	0.00299	CcSEcCtD
Dantrolene—Sweating—Mitoxantrone—lymphatic system cancer	0.00219	0.00297	CcSEcCtD
Dantrolene—Haematuria—Mitoxantrone—lymphatic system cancer	0.00218	0.00296	CcSEcCtD
Dantrolene—Dyspepsia—Fludarabine—lymphatic system cancer	0.00216	0.00293	CcSEcCtD
Dantrolene—Decreased appetite—Fludarabine—lymphatic system cancer	0.00213	0.00289	CcSEcCtD
Dantrolene—Visual impairment—Carmustine—lymphatic system cancer	0.00213	0.00289	CcSEcCtD
Dantrolene—Fatigue—Fludarabine—lymphatic system cancer	0.00211	0.00287	CcSEcCtD
Dantrolene—Constipation—Fludarabine—lymphatic system cancer	0.0021	0.00284	CcSEcCtD
Dantrolene—Pain—Fludarabine—lymphatic system cancer	0.0021	0.00284	CcSEcCtD
Dantrolene—Respiratory failure—Methotrexate—lymphatic system cancer	0.00208	0.00281	CcSEcCtD
Dantrolene—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00206	0.0028	CcSEcCtD
Dantrolene—Hypersensitivity—Teniposide—lymphatic system cancer	0.00206	0.00279	CcSEcCtD
Dantrolene—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00205	0.00278	CcSEcCtD
Dantrolene—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00205	0.00278	CcSEcCtD
Dantrolene—Flushing—Carmustine—lymphatic system cancer	0.00205	0.00278	CcSEcCtD
Dantrolene—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00204	0.00277	CcSEcCtD
Dantrolene—Anaemia—Bleomycin—lymphatic system cancer	0.00204	0.00276	CcSEcCtD
Dantrolene—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00202	0.00274	CcSEcCtD
Dantrolene—Asthenia—Teniposide—lymphatic system cancer	0.002	0.00271	CcSEcCtD
Dantrolene—Malaise—Bleomycin—lymphatic system cancer	0.00199	0.00269	CcSEcCtD
Dantrolene—Pruritus—Teniposide—lymphatic system cancer	0.00197	0.00268	CcSEcCtD
Dantrolene—Leukopenia—Bleomycin—lymphatic system cancer	0.00197	0.00267	CcSEcCtD
Dantrolene—Body temperature increased—Fludarabine—lymphatic system cancer	0.00194	0.00263	CcSEcCtD
Dantrolene—Erythema—Carmustine—lymphatic system cancer	0.00192	0.00261	CcSEcCtD
Dantrolene—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00191	0.00259	CcSEcCtD
Dantrolene—Diarrhoea—Teniposide—lymphatic system cancer	0.00191	0.00259	CcSEcCtD
Dantrolene—Myalgia—Bleomycin—lymphatic system cancer	0.00188	0.00254	CcSEcCtD
Dantrolene—Back pain—Carmustine—lymphatic system cancer	0.00186	0.00252	CcSEcCtD
Dantrolene—Discomfort—Bleomycin—lymphatic system cancer	0.00185	0.00251	CcSEcCtD
Dantrolene—Chills—Mitoxantrone—lymphatic system cancer	0.00184	0.0025	CcSEcCtD
Dantrolene—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00181	0.00246	CcSEcCtD
Dantrolene—Confusional state—Bleomycin—lymphatic system cancer	0.00181	0.00246	CcSEcCtD
Dantrolene—Vision blurred—Carmustine—lymphatic system cancer	0.00181	0.00246	CcSEcCtD
Dantrolene—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00181	0.00245	CcSEcCtD
Dantrolene—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0018	0.00244	CcSEcCtD
Dantrolene—Erythema—Mitoxantrone—lymphatic system cancer	0.00179	0.00242	CcSEcCtD
Dantrolene—Anaemia—Carmustine—lymphatic system cancer	0.00178	0.00241	CcSEcCtD
Dantrolene—Back pain—Vincristine—lymphatic system cancer	0.00178	0.00241	CcSEcCtD
Dantrolene—Vomiting—Teniposide—lymphatic system cancer	0.00177	0.00241	CcSEcCtD
Dantrolene—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00176	0.00239	CcSEcCtD
Dantrolene—Asthenia—Fludarabine—lymphatic system cancer	0.00176	0.00239	CcSEcCtD
Dantrolene—Rash—Teniposide—lymphatic system cancer	0.00176	0.00239	CcSEcCtD
Dantrolene—Dermatitis—Teniposide—lymphatic system cancer	0.00176	0.00238	CcSEcCtD
Dantrolene—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00175	0.00237	CcSEcCtD
Dantrolene—Headache—Teniposide—lymphatic system cancer	0.00175	0.00237	CcSEcCtD
Dantrolene—Pruritus—Fludarabine—lymphatic system cancer	0.00174	0.00235	CcSEcCtD
Dantrolene—Back pain—Mitoxantrone—lymphatic system cancer	0.00173	0.00234	CcSEcCtD
Dantrolene—Leukopenia—Carmustine—lymphatic system cancer	0.00172	0.00233	CcSEcCtD
Dantrolene—Anorexia—Bleomycin—lymphatic system cancer	0.00171	0.00232	CcSEcCtD
Dantrolene—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00171	0.00232	CcSEcCtD
Dantrolene—Anaemia—Vincristine—lymphatic system cancer	0.0017	0.0023	CcSEcCtD
Dantrolene—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00169	0.00228	CcSEcCtD
Dantrolene—Diarrhoea—Fludarabine—lymphatic system cancer	0.00168	0.00227	CcSEcCtD
Dantrolene—Convulsion—Carmustine—lymphatic system cancer	0.00167	0.00226	CcSEcCtD
Dantrolene—Hypertension—Carmustine—lymphatic system cancer	0.00166	0.00225	CcSEcCtD
Dantrolene—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00166	0.00225	CcSEcCtD
Dantrolene—Nausea—Teniposide—lymphatic system cancer	0.00166	0.00225	CcSEcCtD
Dantrolene—Anaemia—Mitoxantrone—lymphatic system cancer	0.00165	0.00224	CcSEcCtD
Dantrolene—Hepatic failure—Methotrexate—lymphatic system cancer	0.00165	0.00223	CcSEcCtD
Dantrolene—Leukopenia—Vincristine—lymphatic system cancer	0.00164	0.00223	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00164	0.00222	CcSEcCtD
Dantrolene—Myalgia—Carmustine—lymphatic system cancer	0.00164	0.00222	CcSEcCtD
Dantrolene—Malaise—Mitoxantrone—lymphatic system cancer	0.00161	0.00219	CcSEcCtD
Dantrolene—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0016	0.00217	CcSEcCtD
Dantrolene—Convulsion—Vincristine—lymphatic system cancer	0.00159	0.00216	CcSEcCtD
Dantrolene—Hypertension—Vincristine—lymphatic system cancer	0.00159	0.00215	CcSEcCtD
Dantrolene—Confusional state—Carmustine—lymphatic system cancer	0.00158	0.00215	CcSEcCtD
Dantrolene—Decreased appetite—Bleomycin—lymphatic system cancer	0.00156	0.00212	CcSEcCtD
Dantrolene—Myalgia—Vincristine—lymphatic system cancer	0.00156	0.00212	CcSEcCtD
Dantrolene—Visual disturbance—Methotrexate—lymphatic system cancer	0.00156	0.00212	CcSEcCtD
Dantrolene—Vomiting—Fludarabine—lymphatic system cancer	0.00156	0.00211	CcSEcCtD
Dantrolene—Convulsion—Mitoxantrone—lymphatic system cancer	0.00155	0.0021	CcSEcCtD
Dantrolene—Rash—Fludarabine—lymphatic system cancer	0.00155	0.0021	CcSEcCtD
Dantrolene—Dermatitis—Fludarabine—lymphatic system cancer	0.00154	0.00209	CcSEcCtD
Dantrolene—Hypertension—Mitoxantrone—lymphatic system cancer	0.00154	0.00209	CcSEcCtD
Dantrolene—Pain—Bleomycin—lymphatic system cancer	0.00154	0.00208	CcSEcCtD
Dantrolene—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00154	0.00208	CcSEcCtD
Dantrolene—Headache—Fludarabine—lymphatic system cancer	0.00154	0.00208	CcSEcCtD
Dantrolene—Tachycardia—Carmustine—lymphatic system cancer	0.00153	0.00208	CcSEcCtD
Dantrolene—Myalgia—Mitoxantrone—lymphatic system cancer	0.00152	0.00206	CcSEcCtD
Dantrolene—Discomfort—Mitoxantrone—lymphatic system cancer	0.0015	0.00204	CcSEcCtD
Dantrolene—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0015	0.00203	CcSEcCtD
Dantrolene—Anorexia—Carmustine—lymphatic system cancer	0.0015	0.00203	CcSEcCtD
Dantrolene—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00148	0.00201	CcSEcCtD
Dantrolene—Confusional state—Mitoxantrone—lymphatic system cancer	0.00147	0.00199	CcSEcCtD
Dantrolene—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00147	0.00199	CcSEcCtD
Dantrolene—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00146	0.00198	CcSEcCtD
Dantrolene—Nausea—Fludarabine—lymphatic system cancer	0.00146	0.00197	CcSEcCtD
Dantrolene—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00145	0.00196	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00143	0.00194	CcSEcCtD
Dantrolene—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00143	0.00194	CcSEcCtD
Dantrolene—Urticaria—Bleomycin—lymphatic system cancer	0.00143	0.00194	CcSEcCtD
Dantrolene—Anorexia—Vincristine—lymphatic system cancer	0.00143	0.00194	CcSEcCtD
Dantrolene—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00142	0.00193	CcSEcCtD
Dantrolene—Body temperature increased—Bleomycin—lymphatic system cancer	0.00142	0.00193	CcSEcCtD
Dantrolene—Insomnia—Carmustine—lymphatic system cancer	0.00142	0.00192	CcSEcCtD
Dantrolene—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00141	0.00191	CcSEcCtD
Dantrolene—Somnolence—Carmustine—lymphatic system cancer	0.0014	0.00189	CcSEcCtD
Dantrolene—Anorexia—Mitoxantrone—lymphatic system cancer	0.00139	0.00189	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00137	0.00185	CcSEcCtD
Dantrolene—Decreased appetite—Carmustine—lymphatic system cancer	0.00136	0.00185	CcSEcCtD
Dantrolene—Insomnia—Vincristine—lymphatic system cancer	0.00136	0.00184	CcSEcCtD
Dantrolene—Constipation—Carmustine—lymphatic system cancer	0.00134	0.00182	CcSEcCtD
Dantrolene—Pain—Carmustine—lymphatic system cancer	0.00134	0.00182	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00133	0.0018	CcSEcCtD
Dantrolene—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00132	0.0018	CcSEcCtD
Dantrolene—Decreased appetite—Vincristine—lymphatic system cancer	0.0013	0.00177	CcSEcCtD
Dantrolene—Somnolence—Mitoxantrone—lymphatic system cancer	0.0013	0.00176	CcSEcCtD
Dantrolene—Feeling abnormal—Carmustine—lymphatic system cancer	0.00129	0.00175	CcSEcCtD
Dantrolene—Fatigue—Vincristine—lymphatic system cancer	0.00129	0.00175	CcSEcCtD
Dantrolene—Asthenia—Bleomycin—lymphatic system cancer	0.00129	0.00175	CcSEcCtD
Dantrolene—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00128	0.00174	CcSEcCtD
Dantrolene—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00128	0.00174	CcSEcCtD
Dantrolene—Pain—Vincristine—lymphatic system cancer	0.00128	0.00174	CcSEcCtD
Dantrolene—Constipation—Vincristine—lymphatic system cancer	0.00128	0.00174	CcSEcCtD
Dantrolene—Pruritus—Bleomycin—lymphatic system cancer	0.00127	0.00172	CcSEcCtD
Dantrolene—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00127	0.00172	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—lymphatic system cancer	0.00127	0.00172	CcSEcCtD
Dantrolene—Fatigue—Mitoxantrone—lymphatic system cancer	0.00126	0.00171	CcSEcCtD
Dantrolene—Constipation—Mitoxantrone—lymphatic system cancer	0.00125	0.00169	CcSEcCtD
Dantrolene—Pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00169	CcSEcCtD
Dantrolene—Abdominal pain—Carmustine—lymphatic system cancer	0.00124	0.00168	CcSEcCtD
Dantrolene—Body temperature increased—Carmustine—lymphatic system cancer	0.00124	0.00168	CcSEcCtD
Dantrolene—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00123	0.00166	CcSEcCtD
Dantrolene—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0012	0.00163	CcSEcCtD
Dantrolene—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00119	0.00162	CcSEcCtD
Dantrolene—Abdominal pain—Vincristine—lymphatic system cancer	0.00118	0.00161	CcSEcCtD
Dantrolene—Body temperature increased—Vincristine—lymphatic system cancer	0.00118	0.00161	CcSEcCtD
Dantrolene—Urticaria—Mitoxantrone—lymphatic system cancer	0.00116	0.00157	CcSEcCtD
Dantrolene—Hypersensitivity—Carmustine—lymphatic system cancer	0.00116	0.00157	CcSEcCtD
Dantrolene—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00115	0.00156	CcSEcCtD
Dantrolene—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00115	0.00156	CcSEcCtD
Dantrolene—Vomiting—Bleomycin—lymphatic system cancer	0.00114	0.00155	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—lymphatic system cancer	0.00114	0.00155	CcSEcCtD
Dantrolene—Depression—Methotrexate—lymphatic system cancer	0.00114	0.00154	CcSEcCtD
Dantrolene—Rash—Bleomycin—lymphatic system cancer	0.00113	0.00154	CcSEcCtD
Dantrolene—Dermatitis—Bleomycin—lymphatic system cancer	0.00113	0.00154	CcSEcCtD
Dantrolene—Asthenia—Carmustine—lymphatic system cancer	0.00113	0.00153	CcSEcCtD
Dantrolene—Renal failure—Methotrexate—lymphatic system cancer	0.00112	0.00152	CcSEcCtD
Dantrolene—Hypersensitivity—Vincristine—lymphatic system cancer	0.0011	0.0015	CcSEcCtD
Dantrolene—Sweating—Methotrexate—lymphatic system cancer	0.00109	0.00148	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—lymphatic system cancer	0.00109	0.00147	CcSEcCtD
Dantrolene—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00108	0.00146	CcSEcCtD
Dantrolene—Asthenia—Vincristine—lymphatic system cancer	0.00108	0.00146	CcSEcCtD
Dantrolene—Diarrhoea—Carmustine—lymphatic system cancer	0.00107	0.00146	CcSEcCtD
Dantrolene—Nausea—Bleomycin—lymphatic system cancer	0.00107	0.00145	CcSEcCtD
Dantrolene—Asthenia—Mitoxantrone—lymphatic system cancer	0.00105	0.00142	CcSEcCtD
Dantrolene—Dizziness—Carmustine—lymphatic system cancer	0.00104	0.00141	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—lymphatic system cancer	0.00103	0.00139	CcSEcCtD
Dantrolene—Diarrhoea—Vincristine—lymphatic system cancer	0.00103	0.00139	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—lymphatic system cancer	0.00102	0.00139	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—lymphatic system cancer	0.00102	0.00139	CcSEcCtD
Dantrolene—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000998	0.00135	CcSEcCtD
Dantrolene—Vomiting—Carmustine—lymphatic system cancer	0.000998	0.00135	CcSEcCtD
Dantrolene—Dizziness—Vincristine—lymphatic system cancer	0.000991	0.00134	CcSEcCtD
Dantrolene—Rash—Carmustine—lymphatic system cancer	0.00099	0.00134	CcSEcCtD
Dantrolene—Dermatitis—Carmustine—lymphatic system cancer	0.000989	0.00134	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—lymphatic system cancer	0.000986	0.00134	CcSEcCtD
Dantrolene—Headache—Carmustine—lymphatic system cancer	0.000983	0.00133	CcSEcCtD
Dantrolene—Vomiting—Vincristine—lymphatic system cancer	0.000953	0.00129	CcSEcCtD
Dantrolene—Rash—Vincristine—lymphatic system cancer	0.000945	0.00128	CcSEcCtD
Dantrolene—Dermatitis—Vincristine—lymphatic system cancer	0.000944	0.00128	CcSEcCtD
Dantrolene—Headache—Vincristine—lymphatic system cancer	0.000939	0.00127	CcSEcCtD
Dantrolene—Nausea—Carmustine—lymphatic system cancer	0.000932	0.00126	CcSEcCtD
Dantrolene—Vomiting—Mitoxantrone—lymphatic system cancer	0.000928	0.00126	CcSEcCtD
Dantrolene—Rash—Mitoxantrone—lymphatic system cancer	0.00092	0.00125	CcSEcCtD
Dantrolene—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000919	0.00125	CcSEcCtD
Dantrolene—Chills—Methotrexate—lymphatic system cancer	0.000918	0.00124	CcSEcCtD
Dantrolene—Headache—Mitoxantrone—lymphatic system cancer	0.000914	0.00124	CcSEcCtD
Dantrolene—Erythema—Methotrexate—lymphatic system cancer	0.000891	0.00121	CcSEcCtD
Dantrolene—Nausea—Vincristine—lymphatic system cancer	0.00089	0.00121	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—lymphatic system cancer	0.000872	0.00118	CcSEcCtD
Dantrolene—Nausea—Mitoxantrone—lymphatic system cancer	0.000867	0.00117	CcSEcCtD
Dantrolene—Back pain—Methotrexate—lymphatic system cancer	0.000862	0.00117	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—lymphatic system cancer	0.00084	0.00114	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000827	0.00112	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—lymphatic system cancer	0.000823	0.00112	CcSEcCtD
Dantrolene—Malaise—Methotrexate—lymphatic system cancer	0.000803	0.00109	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—lymphatic system cancer	0.000797	0.00108	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—lymphatic system cancer	0.000772	0.00105	CcSEcCtD
Dantrolene—Myalgia—Methotrexate—lymphatic system cancer	0.000758	0.00103	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—lymphatic system cancer	0.000749	0.00102	CcSEcCtD
Dantrolene—Confusional state—Methotrexate—lymphatic system cancer	0.000733	0.000994	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000727	0.000986	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000712	0.000965	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000703	0.000953	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—lymphatic system cancer	0.000693	0.000939	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000662	0.000898	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—lymphatic system cancer	0.000658	0.000891	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—lymphatic system cancer	0.000646	0.000876	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—lymphatic system cancer	0.00064	0.000868	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—lymphatic system cancer	0.000632	0.000857	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—lymphatic system cancer	0.000627	0.00085	CcSEcCtD
Dantrolene—Pain—Methotrexate—lymphatic system cancer	0.000622	0.000843	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000599	0.000812	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000595	0.000806	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—lymphatic system cancer	0.000578	0.000783	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—lymphatic system cancer	0.000575	0.000779	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—lymphatic system cancer	0.000575	0.000779	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000536	0.000726	CcSEcCtD
Dantrolene—Asthenia—Methotrexate—lymphatic system cancer	0.000522	0.000707	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—lymphatic system cancer	0.000514	0.000697	CcSEcCtD
Dantrolene—Diarrhoea—Methotrexate—lymphatic system cancer	0.000497	0.000674	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—lymphatic system cancer	0.000481	0.000652	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—lymphatic system cancer	0.000462	0.000627	CcSEcCtD
Dantrolene—Rash—Methotrexate—lymphatic system cancer	0.000458	0.000621	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—lymphatic system cancer	0.000458	0.000621	CcSEcCtD
Dantrolene—Headache—Methotrexate—lymphatic system cancer	0.000455	0.000617	CcSEcCtD
Dantrolene—Nausea—Methotrexate—lymphatic system cancer	0.000432	0.000585	CcSEcCtD
